Search

The article offers information about insomnia. The condition is characterized by difficulty falling asleep, difficulty staying asleep and waking up too early in the morning. Risk factors for insomnia include stressful life events, being old and work shifts. An overview of the causes, diagnosis and treatment of insomnia is also provided.

The article offers information about insomnia. The condition is characterized by difficulty falling asleep, difficulty staying asleep and waking up too early in the morning. A 2003 study suggested there were seven significant factors that predicted high risk for insomnia including being older, being overworked on the job and having a sick relative. An overview of the causes, diagnosis and treatment of insomnia is also provided.

The article offers information about insomnia, which is characterized by difficulty of falling and staying asleep. Insomnia is taken from the Latin words that stand for no sleep. According to some experts, insomnia is also linked with poor quality sleep. Insomniacs can have daytime fatigue, irritability and impaired performance. In the U.S., around 60 million individuals suffer from it. Its medications include non-prescription drugs, Benzodiazepine Hypnotics, antidepressants and other drugs.

Provides information on insomnia. Symptoms of the disease; Brain chemicals and hormones affecting chronic insomnia; Risk factors in elderly adults.

Provides information on several facts about insomnia. Causes of short-term or transient insomnia; Risk factors associated with insomnia; Techniques used in the treatment of insomnia. INSETS: Healthy Sleep;Sleep Hygiene Tips;Warnings on Alternative and So-Called Natural Remedies;Treating Children with Insomnia

Presents information on depressive disorders. Symptoms of major depression; Characteristics of dysthymia and seasonal affective disorder; Factors that cause depression; Relationship of depression with insomnia; Depression in women.

Provides information on insomnia. Symptoms; Forms; Causes of short-term or transient insomnia; Treatments. INSETS: Healthy Sleep;Treatment of Specific Groups.

Provides information on insomnia. Causes of chronic insomnia; Role of fluctuations in female hormones in insomnia in women; Drug treatments. INSETS: Healthy Sleep;Sleep Hygiene Tips;Warnings on Alternative and So-Called Natural Remedies;Treatment of Specific Groups

Provides information on insomnia. Causes of transient or short-term insomnia; Diagnosis; Behavioral and other non-drug treatments. INSETS: Healthy Sleep;Sleep Hygiene Tips;Warnings on Alternative and So-Called Natural Remedies;Treatment of Specific Groups

This article presents news briefs related to nervous system diseases. One of the snippets report that Sepracor Inc.'s sleep aid drug Lunesta may be a cost effective treatment for chronic insomnia. Lunesta is the first and only sleep aid approved by the U.S. Food and Drug Administration (FDA)for long-term use. Another snippet focuses on Neurocrine Biosciences Inc. which has completed the submission of its FDA application to market indiplon tablets for the treatment of insomnia in both adult and elderly patients. The company began submitting data for the application in April 2005. The findings are based on clinical data supporting that both indiplon capsules and tablets show significant improvement in all sleep onset, sleep maintenance and sleep quality parameters.

The article presents results of clinical trials for different drugs. The failure of Aphton Corp.'s investigational immunotherapy Insegnia to improve survival in pancreatic cancer patients has affected its shares. OxiGene Inc. has released a new preclinical data showing that its lead compound CA4P combined with Avastin can enhance anti-tumor activity. Neurocrine Biosciences Inc. has announced positive results of the phase III study with indiplon tablets for chronic insomnia.

Ramelteon Tablets are used for the treatment of insomnia characterized by difficulty with sleep onset [ABSTRACT FROM AUTHOR]

Ramelteon Tablets are used for the treatment of insomnia characterized by difficulty with sleep onset [ABSTRACT FROM AUTHOR]

The article reports on the closure of the joint development program of Merck & Co. Inc. and Lundbeck for gaboxadol, an investigational new medicine for the treatment of insomnia in the U.S. According to the companies, the data from recently completed clinical studies that overall profile for gaboxadol in insomnia does not support further development. Both companies will not file a new drug application for gaboxadol for the treatment of insomnia.

The article offers news briefs related to the development of drugs by pharmaceutical industry in the U.S. Somaxon Pharmaceuticals Inc. succeed in its phase III clinical trial of Silenor for insomnia. Neurogen Corp. started the phase II clinical trial for NG2-73, a medicine for chronic insomnia patients. Hypnion Inc. finished the initial phase II trial of HY10275 for adults with insomnia.

The article reports that the drug paliperidone ER is beneficial in the treatment of insomnia. The drug is manufactured by Johnson & Johnson. Paliperidone is the first and only atypical antipsychotic which has used an extended-release technology named OROS. Trials of the drug have shown significant improvements in mean sleep measurements compared to placebo.

The article provides update in sleep disorders in the U.S. The investigational drug Gaboxadol being developed by Merck & Co. Inc. and H LundbeckA/S company has show to improve deep sleep and key sleep measures in phase II trial in adult patients with both primary and transient insomnia. A study showed that the Sanofi Aventis SA's insomnia drug Ambien CR is well-tolerated and effective in improving sleep onse and maintenance for 6 months in patients with chronic primary insomnia.

The article focuses on the results of a clinical trial of Lunesta, a product of Sepracor Inc. for the treatment of insomnia. It has been concluded in the clinical trial of Lunesta that it is effective in treating insomnia in patients suffering from rheumatoid arthritis. Evaluating Lunesta's ability to treat insomnia in patients with rheumatoid arthritis formed part of Sepracor's initiative to differentiate the drug from other hypnotics. Statistically, a significant improvement was produced by the Lunesta in the trial in comparison with placebo in patient reported measures of sleep latency, wake time after sleep onset, total sleep time and sleep quality.

The article presents news briefs on clinical developments related to the treatment of sleep disorders. A clinical study on neuro-active compound is conducted by Evotec Biosystems AG in healthy participants. The study demonstrates both the safety and efficacy of the product as a potential treatment for insomnia. According to new researches, insomnia often affect the quality of life for older people leading many to rely on commonly used tranquilizers such as benzodiazepines. The study was mainly carried upon those people who are aged 60 and above.

The article presents information about the research and developments undertaken to cure sleep disorders. Ambien CR, an extended-release formulation of the popular prescription sleep aid Ambien, is now available by prescription in pharmacies across the United States for the treatment of insomnia. Ambien CR is the product of Sanofi-Aventis SA. A clinical trial will be conducted by Somaxon Pharmaceuticals Inc. on Silenor, which is the company's investigational candidate for the treatment of insomnia. The trial will evaluate the safety and efficacy of Silenor over a three month period in elderly patients diagnosed with primary chronic insomnia.

Presents news briefs related to sleeping disorders. Information on the U.S. Food and Drug Administration's approval of Sanofi-aventis SA's Ambien CR, which is an improved formulation of the company's popular insomnia medication, Ambien; Discussion on the safety and efficacy of zolpidem, the active ingredient in Ambien CR; Disorders associated with both neurological and psychological diseases.

The article reports that a new drug application for an insomnia treatment produced by Neurocrine Biosciences Inc. has been accepted for review by the U.S. Food and Drug Administration. The company is seeking approval to market Indiplon capsules for the use of both adult and elderly patients. Indiplon was developed to address different types of sleep problems. Indiplon was licensed from DOV Pharmaceutical Inc. in 1998. If the FDA accepts both applications for review, approval decisions could be made half way through 2006.

The article reports on the financial performance of Lundbeck Pharmaceuticals in 2005. The company announced a 39 percent decline in its net profit. Despite the decline in profits and revenues the company has high hopes on its Gaboxadol, which holds considerable potential in the treatment of insomnia and planning to penetrate the U.S. and Japanese markets and establish its own sales force for the first time in these countries.

H. Lundbeck AS and Merck & Co. Inc. have negotiated an extension of their agreement for the exclusive development and commercialization of sleep disorder compound gaboxadol to Japan. Under the terms of the extended agreement, Merck and Lundbeck will jointly conduct the clinical program required for filing a new drug application in Japan, with Merck funding the majority of the development activities. Gaboxadol, a direct-acting GABA-A receptor agonist, is expected to be the first product launched in the class. It has a mode of action different from that of benzodiazepine receptor ligands presently on the market or nearing launch.

Reports on developments related to pharmaceutical biotechnology industry in the U.S. as of June 2004. Potential of Pfizer Inc.'s cholesterol-lowering medication, Lipitor to slow the progression and deterioration rates presenting in Alzheimer's disease; Safety and efficacy of Ambien, the leading prescription sleep aid developed by Sanofi-Synthelabo SA for the treatment of insomnia; Results of a study of AstraZeneca PLC which supported the use of a Seroquel monotherapy targeting maniac episodes associated with bipolar disorder.

Focuses on the preliminary positive results from the two Phase III trials of indiplon for treatment of insomnia initiated by Neurocrine Biosciences Inc. Efficacy of the immediate and modified release of the drug; Schedule for the launching of the drug; Number of patients involved in the study.

Unveils the results of Neurocrine Biosciences Inc.'s phase III clinical trial with two doses of the immediate release formulation of indiplon designated for the treatment of chronic insomnia. Measurement of the latency to sleep onset of patients; Response of elderly patients taking indiplon; Demonstration of the safety and efficacy of indiplon in treating elderly patients who experience chronic insomnia.

Presents news updates on sleep disorders, compiled as of December 2003. Effectiveness of Neurocrine Biosciences' Indiplon for treating insomnia; Effectiveness of Cortex Pharmaceuticals' Ampakine CX516 in a human sleep deprivation study.

Reports on the new drug application filed by Sepracor Inc. with the U.S. Food and Drug Administration for Estorra as treatment for insomnia. Likelihood of the drug to receive a low uptake because of a lack of marketing power; Demonstration that Estorra made patients fall asleep and stay asleep through the night in the clinical trial initiated by the company; Competition faced by the drug with indiplon from Neurocrine Biosciences Inc. and Pfizer Inc.

The article reports positive Phase III data for Merck & Co.'s insomnia candidate suvorexant, offering hope for the drug after speculation about class-wide safety issues. Results suggest that patients taking suvorexant for 12 months and who were immediately switched to placebo did not suffer from significant withdrawal symptoms and rebound insomnia. Secondary efficacy measures also found that patients taking suvorexant fell asleep faster, stayed asleep longer and spent less time awake at night.

The article lists several reports and company profiles related to the central nervous system (CNS) pharmaceutical industry including the report entitled "Epidemiology: Insomnia," another concerning the research and development trends of bipolar disorders, and the company profile of Eisai Co. Ltd.

The article reports that the U.S. National Transportation Safety Board (NTSB) has issued several recommendations to the U.S. Federal Aviation Administration (FAA), after the crash of a Hawker Beechcraft 125-800A twin-engine business jet. It states that the rules require operators to ensure that the pilots stick to the standard operating procedures. It also recommends a review of policy standards for all common sleep-related conditions, including insomnia.

The article reports on the plan of Sepracor, a research-based company in the U.S., to progress the insomnia drug Lunesta into Europe and Japan. It stated that Lunesta was submitted to the European Medicines Agency (EMEA) under the brand name Lunivar after two six-month placebo controlled studies. Moreever, insomnia is defined as the perception or complaint of inadequate or poor quality sleep due to difficulty falling to sleep, waking up at early hours, and un-refreshing sleep.

A list of reports related to pharmaceutical industry is presented. They include "Commercial Insight: Insomnia Strong brand identity critical to differentiation in an increasingly crowded market," "Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment," and "Neuroprotection in Stroke - Protecting the Brain Sells."

The article reports on the submission of a authorization application for insomnia medication ramelteon by Takeda Pharmaceutical to the European Medicines Agency in Europe. U.S. Food and Drug Administration approved Ramelteon in July 2005. It is being marketed by Takeda as Rozerem but the European brand name for ramelteon is yet to be confirmed.

The article discusses the clinical trial results for Acadia Pharmaceuticals' insomnia treatment ACP-103. The results suggest that ACP-103 has potential to induce a robust and statistically significant increase in slow wave sleep in healthy volunteers. ACP-103 is a selective receptor inverse agonist that acts to block the activity of serotonin receptors.

The article reports on the positive clinical trials results for the ACP-103 insomnia treatment of Acadia Pharmaceuticals. The activity of serotonin receptors are blocked by the action of ACP-103 which is a selective receptor inverse agonist. Sleep quality is improved by increasing slow wave sleep. The drug has a positive impact on measures for sleep maintenance, with the number of awakenings after sleep onset decreasing.

This article presents a list of publications related to the pharmaceutical industry. Some of the publications are: "Commercial Insight: ADHD: Strattera Will Reign Supreme When Branded Stimulants Slump"; "Pipeline Insight: Neuropathic Pain: Pipeline Drugs Fail to Nail Neuropathic Pain"; "Pipeline Insight: ADHD: Shire Driving Diversity in ADHD"; "Neuroprotection in Stroke: Protecting the Brain Sells"; "Top CNS Portfolios in 2004: The Industry Gold Standards"; and "Restless Legs Syndrome: Recognition Lacking Still."

The article presents a list of various reports and briefs related to drugs. Some of the reports are: "Pipeline Insight: Neuropathic Pain--Pipeline Drugs Fail to Nail Neuropathic Pain," "Pipeline Insight: ADHD--Shire Driving Diversity in ADHD," "Commercial Insight: Migraine--A Painful Future for the Triptans?" and "Urinary Incontinence: Major Milestones." Some of the briefs are: "Tropical and Defense Vaccines--The Scared, the Weak and the Poor," "Restless Legs Syndrome--Recognition Lacking Still" and "Insomnia--Wake-Up Call for a Sleepy Market."

Reports that Eli Lilly & Co. has received exclusive rights to develop and market Merck KGaA's EMD-281014 insomnia drug. Potential of the company to generate revenues through its insomnia drug; Efficacy of insomnia drug; Confidence of the company that EMD-281014 represents a novel approach to treating insomnia.

Lists several research papers on the development of drugs for the treatment of central nervous system diseases. Provision of an overview of the epidemiology of insomnia in the research "Insomnia - Wake-Up Call for a Sleepy Market"; In-depth profiles of market-leading brands in the research "Commercial Perspectives: Multiple Sclerosis - How to Find Opportunities in an Unremitting Market"; Examination of the epidemiology and potential market size for the treatment of postoperative pain in the research "Postoperative Pain: Dynastat Cutting Up the Pain Market".

Presents literature related to central nervous system disorder. Epidemiology of Alzheimer's disease; Epidemiology of insomnia to assess the untapped patient potential offered by the disorder; Analysis of epidemiology of urinary incontinence, by sub-indications, with an evaluation of the potential for expanding the diagnosed population.

On February 27, 2004, Sepracor Inc. received an approvable letter from the Food and Drug Administration (FDA) for its new drug application (NDA) for Estorra for the treatment of insomnia characterized by difficulty falling asleep and/or difficulty maintaining sleep during the night and early morning. Under the Prescription Drug User Fee Act (PDUFA), the FDA has 14 days after resubmission of an NDA to evaluate the submission in order to determine if it is sufficiently complete and whether it will receive a class 1 or longer class 2 review. The NDA contains a total of 24 clinical trials, which included more than 2,700 adult and elderly subjects, and more than 60 preclinical studies.

Reports on the efficacy of Indiplon insomnia drug developed in partnership of Neurocrine Biosciences Inc. and Pfizer Inc. in the U.S. Significance of the drug to help insomnia patients fall asleep faster and longer with minimal disturbance; Composition of the drug with GABA neurotransmitter modulator; Marketing capabilities of the drug.